PPT-COVID-19/SARS-CoV-2 & back to school

September 3 2020 Dr Dawn Bowdish PhD Canada Research Chair in Aging amp Immunity McMaster University bowdishmcmasterca wwwbowdishca Twitter amp Instagram MsMacrophage . CTropMed. 3/17/20. COVID-19. SARS-CoV-2. 2019-nCov. HCoV-19. Disease. Virus Name. 7 Human Coronaviruses:. 4 normal; 3 “novel”. Alpha: . HCoV-229E. , . HCoV-NL63 . Beta: . HCoV-HKU1. , . HCoV-OC43. Page 9 Yan Leyfman 1 , Timothy K. Erick 1 , Pushpa Sharma 1,2 1 WACEM-ACAIM Joint Global COVID-19 Taskforce— Immunology Division, USA 2 Department of Anaesthesiology, Uniformed Services Universit January 2 7 , 202 1 Page | 1 d for Standar Final 220, - 16VAC25 Infectious Disease Prevention of the SARS - CoV - 2 Virus That Causes COVID - 19 As Adopted by the Safety and Health Codes Board on January 272021Page 1d forStandarFinal 220 -16VAC25Infectious Disease Preventionofthe SARS-CoV-2 Virus That Causes COVID-19As Adopted by theSafety and Health Codes Boardon January 13 2021VIRGINIA OCCU 2 In the event that the medical doctor confirms it arrangements must be made with the Mobile Emergency so that the employee with symptoms quickly leaves the Plant and the family and the corresponding DiagnoscsDo not re-useTo indicate the temperature limitaons in which the transport package has to be kept and handledConsult Instrucons for UseContains Sucient fxn000or estsManufacturerBatch codeUse The more the virus circulates, the more the virus will evolve
Most changes have little to no impact on the virus’s properties or behaviour
However, some changes to SARS-CoV-2 lead to the emergence of variants that may affect: May 27. 2020. K.Dharmalingam. Asymptomatic Likely but remote. Prodromal Yes. Oligosymptomatic Yes. Polysymptomatic Yes. Spread occurs from all these groups of patients. Fauci. , for one, still believes it does.. An Initiative of DBT-AIs. Coordinated by . National Institute of Biomedical Genomics (NIBMG), . Kalyani. . P. articipating Institutes:. Teams:. . . NIBMG:. . Arindam. . Maitra. , . Nidhan. Biswas, . A drug repurposing approach for COVID-19. Md. Riad Chowdhury. 1. , . Md. . Adnan. 2,*. , . Md. Nazim Uddin . Chy. 1,*. , . A.T.M. Mostafa Kamal. 1. 1. Department of Pharmacy, International Islamic University Chittagong, . 1614 calculations need be made using demo graphic and epidemiological data. For example, with the recorded case fatality rates in the UK during the rst COVID-19 wave and with the UK demography, - CoV - 2 Patricia Slev, PhD, D(ABCC) Section Chief, Immunology, ARUP Laboratories Associate Professor, University of Utah School of Medicine patricia.slev@aruplab.com 1 DISCLOSURES P Slev None OBJEC . alberto.tommasini@burlo.trieste.it. Trieste, 24 NOVEMBRE 2021. SARS-CoV-2. Enveloped, with a . ssRNA. genome. 4 Coronavirus genera. Alphacoronavirus. (Mammals). 229E and NL63. Betacoronavirus. (Mammals). (virus). Guam Department of Public Health and Social Services. Disclaimer: This is a rapidly evolving situation. Information and guidance are constantly changing. Information presented in these slides may already be out-of-date..